Login to Your Account



Index Pharma gets $20M for ulcerative colitis DNA drug

By Cormac Sheridan
Staff Writer

Tuesday, February 25, 2014
With phase III data from ulcerative colitis DNA-based drug Kappaproct (DIMS0150) due in the coming months, Index Pharmaceuticals AB has added $20 million to its balance sheet in advance.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription